Contact Us
Drug Search Results
More Filters [+]

Flutemetamol (18f)

Alternative Names: flutemetamol (18f), 18f-flutemetamol, flutemetamol f 18, flutemetamol f18, flutemetamol, [18f]flutemetamol, vizamyl
Latest Update: 2024-12-17
Latest Update Note: Clinical Trial Update

Product Description

Flutemetamol F 18 is a radiopharmaceutical containing flutemetamol, a thioflavin derivative of Pittsburgh compound B (PiB) labeled with the radioisotope fluorine F18 that can be used to detect beta-amyloid deposition upon positron emission tomography (PET).  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Flutemetamol-F-18)

Mechanisms of Action: APP Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Hungary | Iceland | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Poland | Portugal | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | United States

Approved Indications: None

Known Adverse Events: None

Company: GE Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Flutemetamol (18f)

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Amyloidosis

Phase 1: Cardiomyopathies

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
pulsar

P2

Active, not recruiting

Amyloidosis

2025-07-19

NCT05374564

P1

Recruiting

Cardiomyopathies

2025-06-01

Recent News Events

Date

Type

Title

12/02/2024

News Article

 GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical

09/27/2024

News Article

 GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease

05/10/2023

News Article

 Increasing Use of PET Scans for Diagnosis to Boost PET Radioactive Tracers Market to US$1.92 Billion by 2033, Persistence Market Research

01/15/2020

News Article

 Life Molecular Imaging announces presentation of new scientific data at the Human Amyloid Imaging Meeting

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions